FI932351A - Cyklopeptider och deras anvaendning som resorptionsbefraemjande medel vid applikation pao slemhinnor - Google Patents

Cyklopeptider och deras anvaendning som resorptionsbefraemjande medel vid applikation pao slemhinnor Download PDF

Info

Publication number
FI932351A
FI932351A FI932351A FI932351A FI932351A FI 932351 A FI932351 A FI 932351A FI 932351 A FI932351 A FI 932351A FI 932351 A FI932351 A FI 932351A FI 932351 A FI932351 A FI 932351A
Authority
FI
Finland
Prior art keywords
formula
slemhinnor
resorptionsbefraemjande
cyclopeptider
medel
Prior art date
Application number
FI932351A
Other languages
English (en)
Finnish (fi)
Other versions
FI932351A0 (fi
Inventor
Juergen Dr Sandow
Walter Dr Duerckheimer
Guenter Dr Ditzinger
Hans-Peter Prof Merkle
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI932351A0 publication Critical patent/FI932351A0/fi
Publication of FI932351A publication Critical patent/FI932351A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62Polymyxins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
FI932351A 1992-05-26 1993-05-24 Cyklopeptider och deras anvaendning som resorptionsbefraemjande medel vid applikation pao slemhinnor FI932351A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4217350 1992-05-26

Publications (2)

Publication Number Publication Date
FI932351A0 FI932351A0 (fi) 1993-05-24
FI932351A true FI932351A (fi) 1993-11-27

Family

ID=6459729

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932351A FI932351A (fi) 1992-05-26 1993-05-24 Cyklopeptider och deras anvaendning som resorptionsbefraemjande medel vid applikation pao slemhinnor

Country Status (18)

Country Link
US (1) US5565423A (es)
EP (1) EP0571921B1 (es)
JP (1) JPH0672899A (es)
KR (1) KR940005669A (es)
AT (1) ATE144991T1 (es)
AU (1) AU665676B2 (es)
CA (1) CA2096889A1 (es)
DE (1) DE59304389D1 (es)
DK (1) DK0571921T3 (es)
ES (1) ES2096140T3 (es)
FI (1) FI932351A (es)
GR (1) GR3021570T3 (es)
HU (1) HUT64776A (es)
IL (1) IL105795A (es)
NO (1) NO931888L (es)
NZ (1) NZ247680A (es)
TW (1) TW274552B (es)
ZA (1) ZA933629B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
JP2005524649A (ja) * 2002-02-25 2005-08-18 カイロン コーポレーション Mc4−rアゴニストの鼻腔内投与
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2683517A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN103946233A (zh) 2011-11-18 2014-07-23 诺瓦克塔生物系统有限公司 多黏菌素衍生物
EP2999711B1 (en) 2013-05-22 2022-06-29 Spero Therapeutics, Inc. Polymyxin derivatives and their use in combination therapy together with different antibiotics
FI126143B (en) * 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
SI3810633T1 (sl) 2018-06-25 2024-04-30 Spero Therapeutics, Inc. Spojine
EP3973990A4 (en) * 2019-03-25 2023-07-19 University of Tsukuba PROMOTOR FOR PERMEATION INTO A CELL LAYER, COMPOSITION TO ENABLE DRUG ABSORPTION AND PHARMACEUTICAL COMPOSITION
CN117649950B (zh) * 2024-01-29 2024-05-17 北京大学第三医院(北京大学第三临床医学院) 一种催产素药物作用动力学模型及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2124060B1 (es) * 1971-02-02 1974-04-12 Rhone Poulenc Sa
WO1988000950A2 (en) * 1986-08-06 1988-02-11 Fauchere Jean Luc Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
DE3726324A1 (de) * 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates

Also Published As

Publication number Publication date
IL105795A (en) 1998-03-10
ZA933629B (en) 1993-12-20
ATE144991T1 (de) 1996-11-15
NO931888D0 (no) 1993-05-25
ES2096140T3 (es) 1997-03-01
HU9301520D0 (en) 1993-09-28
AU665676B2 (en) 1996-01-11
GR3021570T3 (en) 1997-02-28
JPH0672899A (ja) 1994-03-15
EP0571921A3 (es) 1994-01-12
NO931888L (no) 1993-11-29
FI932351A0 (fi) 1993-05-24
NZ247680A (en) 1995-07-26
IL105795A0 (en) 1993-09-22
HUT64776A (en) 1994-02-28
DE59304389D1 (de) 1996-12-12
EP0571921A2 (de) 1993-12-01
TW274552B (es) 1996-04-21
CA2096889A1 (en) 1993-11-27
DK0571921T3 (da) 1997-04-01
EP0571921B1 (de) 1996-11-06
AU3876693A (en) 1993-12-02
KR940005669A (ko) 1994-03-22
US5565423A (en) 1996-10-15

Similar Documents

Publication Publication Date Title
FI932351A (fi) Cyklopeptider och deras anvaendning som resorptionsbefraemjande medel vid applikation pao slemhinnor
ATE147756T1 (de) Neue oral wirksame elastase-inhibitoren
DK0948527T3 (da) Cylosporinderivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
HUP0100100A2 (hu) Hepatitis C inhibitor peptid-analógok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69218977D1 (de) Trifluoromethylketon-Tripeptidderivate
ES2091359T3 (es) Nuevo compuesto peptidico y un procedimiento para su preparacion.
ATE209034T1 (de) Taxolderivate
ATE202784T1 (de) Streptogramine in gereinigter form, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE89549T1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
WO1998019673A3 (en) Anti-viral agents and methods relating to the use thereof
DK0548790T3 (da) (1S)-hydroxyalkyloxapenem-3-carboxylsyrer og deres anvendelse som betalactamasehæmmere
ATE95169T1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.